The estimated Net Worth of Sylvia Mcbrinn is at least $27.1 Tysiąc dollars as of 26 December 2023. Sylvia Mcbrinn owns over 4,000 units of BioAtla stock worth over $27,074 and over the last 3 years Sylvia sold BCAB stock worth over $0.
Sylvia has made over 6 trades of the BioAtla stock since 2022, according to the Form 4 filled with the SEC. Most recently Sylvia bought 4,000 units of BCAB stock worth $9,320 on 26 December 2023.
The largest trade Sylvia's ever made was buying 4,000 units of BioAtla stock on 26 December 2023 worth over $9,320. On average, Sylvia trades about 1,870 units every 47 days since 2021. As of 26 December 2023 Sylvia still owns at least 15,125 units of BioAtla stock.
You can see the complete history of Sylvia Mcbrinn stock trades at the bottom of the page.
Sylvia's mailing address filed with the SEC is C/O BIOATLA, INC. 11085 TORREYANA ROAD, , SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B... oraz Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BioAtla executives and other stock owners filed with the SEC include: